Amy Abernethy - Dec 17, 2021 Form 4 Insider Report for EQRx, Inc. (EQRX)

Role
Director
Signature
/s/ William Collins, Attorney-in-Fact
Stock symbol
EQRX
Transactions as of
Dec 17, 2021
Transactions value $
$0
Form type
4
Date filed
12/21/2021, 05:30 AM
Previous filing
Aug 3, 2021
Next filing
Feb 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EQRX Class A Common Stock Options Exercise +200K 200K Dec 17, 2021 Direct F1
transaction EQRX Class A Common Stock Other -200K -100% 0 Dec 17, 2021 Direct F2
transaction EQRX Common Stock Other +200K 200K Dec 17, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EQRX Class B Common Stock Options Exercise -200K -100% 0 Dec 17, 2021 Class A Common Stock 200K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion").
F2 Immediately following the Conversion but prior to Closing, the Class A Common Stock was reclassified as Common Stock.

Remarks:

Exhibit 24 - Power of Attorney